disopyramide has been researched along with Cyanosis in 1 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Cyanosis: A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Under continuous ECG and oxygen saturation (SpO2) monitoring, the following measurements were taken by Doppler echocardiography in 6 consecutive patients with tetralogy of Fallot (TF) before and after intravenous administration of disopyramide (2mg/kg): left ventricular shortening fraction (LVSF); peak velocities in the right ventricular outflow tract (RVOT); diastolic and systolic internal diameters of the right ventricular outflow tract (dRVOT, sRVOT); and systolic blood pressure." | 7.70 | Disopyramide: a promising new approach to the medical treatment of the hypercyanotic spell complicating tetralogy of Fallot. ( Chiba, S; Fuse, S; Hatakeyama, K; Suzuki, M; Tomita, H, 1998) |
| "Under continuous ECG and oxygen saturation (SpO2) monitoring, the following measurements were taken by Doppler echocardiography in 6 consecutive patients with tetralogy of Fallot (TF) before and after intravenous administration of disopyramide (2mg/kg): left ventricular shortening fraction (LVSF); peak velocities in the right ventricular outflow tract (RVOT); diastolic and systolic internal diameters of the right ventricular outflow tract (dRVOT, sRVOT); and systolic blood pressure." | 3.70 | Disopyramide: a promising new approach to the medical treatment of the hypercyanotic spell complicating tetralogy of Fallot. ( Chiba, S; Fuse, S; Hatakeyama, K; Suzuki, M; Tomita, H, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomita, H | 1 |
| Fuse, S | 1 |
| Hatakeyama, K | 1 |
| Suzuki, M | 1 |
| Chiba, S | 1 |
1 other study available for disopyramide and Cyanosis
| Article | Year |
|---|---|
Disopyramide: a promising new approach to the medical treatment of the hypercyanotic spell complicating tetralogy of Fallot.
Topics: Blood Flow Velocity; Blood Pressure; Child, Preschool; Cyanosis; Disopyramide; Echocardiography, Dop | 1998 |